Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Placenta enriched 4 (PLAC4) is a gene highly expressed in the placenta, also referred to as placenta-specific protein 4 or C21orf115[7]. It is classified as a long non-coding RNA (lncRNA) gene, although some annotations list protein products; its precise biological function remains unclear[7]. PLAC4 is often used as a marker of placental tissue in transcriptome studies, but there is no evidence it functions as a therapeutic target, nor are there reports of interaction with drugs or association with any disease. It is primarily noted for its specificity to placental tissue and is not implicated in signal transduction, metabolism, or receptor activity pathways[7]. There are no documented safety or clinical concerns pertaining to PLAC4.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Placenta enriched 4 (PLAC4).